## **General Treatment Planning**

A.Mazal, L.DeMarzi, N.Fournier-Bidoz, S.Delacroix, S.Zefkili, C.Nauraye, M.Robilliard, G.Gaboriaud, R.Ferrand, J-C.Rosenwald, R.Dendale, L.Desjardins, A.Fourquet

### **Institut Curie, Paris, France**

Acknowledgments: M.Goitein, B.Schaffner, M.Engelsman, N. Schreuder, E.Roelofs, A.Trofimov, J.Flanz, H.Paganetti, H.Kooy, J.Adams, Z.Tochner, E.Hug, H.Giap, Canceropôle, Rococo, France Hadron IBA, Varian, Dosisoft, Areva

# institut**Curie**

PTCOG52 Essen 2013

# Menu of today

- The process of planning
- Some differences with protons
- Calculating models
- Compensators : "smearing"
- Limitations of protons
- Basics of planning
- (If time :
  - TPS validation & QA,
  - Management of organ movement )



What can we see when we are used to plan with photons ... and move to protons? (1 beam, concepts ~ valid for passive and active techniques...)



(Sub)liminal message

## **BUT PLANNING**

## **IS NOT ONLY**

### **ISODOSES** and **HISTOGRAMS**



<u>The planning process :</u>

### <u>« First simple case » : Ophthalmologic tumors</u>

*Imaging Obtain and inter-register imaging studies : CT, MRI, fundus, angiography, ultrasound* 





*Immobilisation & reference coordinates :* 

masks, frames,... and/or...

Use of implanted fiducials









### Delineate target, planning aims and beam design



## Daily set-up control



|                      | step |                                      |
|----------------------|------|--------------------------------------|
|                      | 1    | Evaluate the patient                 |
|                      | 2    | Register Images in tt position       |
|                      | 3    | Delineate target and critical organs |
|                      | 4    | Establish the planning aims          |
| ĺ                    | 5    |                                      |
|                      | →    | Design beams                         |
| ,<br> <br> <br> <br> | 6    | Evaluate, replan                     |
| ĺ                    | 7    | Finalize the prescription            |
|                      | 8    | Simulate, QA                         |
|                      | 9    | Deliver, record, verify              |
|                      | 10   | Re-evaluate during treatment         |
|                      | 11   | Document, archive                    |
|                      | 12   | Review during follow-up              |

#### The planning process in general

(adapted from M.Goitein)

Steps are common for any approach in RT...





# **TPS** : beam models



### **Broad beam algorithm - Concept**



institut**Curie** 

Ray tracing :

straight protons (no scattering), coming from a ponctual source

\* latéral pénumbra model => takes into account scattering due to :

- initial beam line
- compensator + air-gap
- patient
- $\Rightarrow$  Limitations in inhomogeneous areas and for compensator gradients







 $\Rightarrow$  Old, simple, fast and relatively efficient

### 2) Pencil Beam

## Eclipse pencil beam algorithm - Concept



- Principle
  - Convolution of 3D undisturbed proton fluence in air with a 'beamlet' in water.
- In practice
  - Superposition of inhomogeneity corrected beamlets and multiplication with fluence at calculation position.



Pencil Beam :

• Scattering = broadening of each pencil beam ( $\Leftrightarrow$  increase of the  $\sigma$  as a function of depth & upstream parameters)

- Good compromise speed-precision:
- well-suited for compensator
- « smoothes » isodose curves

The most used at present





# **TPS** beam models : Monte Carlo

Tracking each particle and all interactions (Geant 4, MCNPX,...):

- Beam at the entrance (E,dE,...)
- Treatment Head/nozzle
- 4D if movements
- Patient CT:
  - HU  $\rightarrow$  groups of tissues



Paganetti, Bernardz, et al



0 5 10 (van Lujik et al)





Comparison PB-MC (Paganetti, Trofimov, et al

#### **Applications of Monte Carlo :**



Precise dose calcs with inhomog



Calculation of neutrons



Tissue activation for PET QA



Calculation of LET  $\rightarrow$  RBE



Conversion from water to tissue dose

Bednardz, PTCOG49 / (Data from Paganetti, Shin, Espana, Oelfke, Athar, Xu and Bolch)

# The planning process in general – and the differences between protons and x-rays



(from M.Goitein)



### Plot of calculated (HU<sub>sc</sub>,SP<sub>rel</sub>) pairs and linear fits















#### Ex of a compensator



2nd reason to smear : Mis alignements and/or organ movement

 $\rightarrow$  See at the end, or other presentations in this course



# **TPS : Compensator design**

- 1. Geometrical ray-tracing (taking inhomogénities into account)
- 2. Smearing (2-> 6 mm) :

compensates for uncertainties, scattering, movements ||

- 3. Dealing with borders (no target)
- 4. Tool simulation ( $\Leftrightarrow$  2<sup>nd</sup> smearing)
- 5. Milling file generation
- 6. QA (mechanical, radiological, measurements...)





Tool simulation





**Borders** 

But... if « complex » heterogeneities : not only a « ray tracing approach », also multiple scattering effects :





### Patient Contour



### Properties of planning with passive beams

Good lateral penumbra (~10-15 %/mm) shaped by aperture

\* « 2,5 D » tumor shaping (lateral and distal shaping, not proximal)

 Lateral penumbra sensitive to air gap (between aperture and patient)

With this approach:

- $\Rightarrow$  Get profit of proton characteristics
- $\Rightarrow$  Minimize risks and drawbacks
- $\Rightarrow$  Not using the full « potential » of protons





## Limits: Degradation of balistic properties

Entrance dose 80 (& small buildup) 60 40 20 0 120 Small field size Dose [Rel.Units] 100 < peak/entrance 80 60 40 20 n n 2 Degradation After complex Inhomogeneities (and problem of CT artifacts)



⇒ Check that TPS takes all this into account



Effect of density changes (eg : in the target volume or in the beam path)



Similar effects for CT artifacts, contrast, mispositioning or organ movement

Need to survey the anatomical changes in the path after the planning CT and till the end of the treatment



# **Planning basics**

# **Abbuting fields**



# **Patch fields**



Lateral penumbra + Lateral penumbra

Distal penumbra + Lateral/distal penumbra



## <u>Clinical applications:</u> <u>Eg: Base of the skull tumors</u>

### Non coplanar beams

**Photons-protons** 

## Junctions, patching

















### **CONFORMAL P**







## General planning tricks and some useful rules

- ★ Entrance dose (++) =>
- multiply the ports, combine with photons
- \* Patch fields risky (hot & cold spots) =>
- limit the dose/patch (eg < 8 CGE)
- design several patch fields
- Uncertainties on distal edge position (mask, inhomogeneities) + RBE =>
- don't stop beams with high dose in front of OAR (if possible...)

\* avoid « risky » ports (through nose, tongue, …)





# Practical examples (CPO)



DOSIsoft Isogray - version 3.1.beta0024-CP0009 Patient: AXEL ADOU ID: 07357 Etude: compisis\_isogray\_v31

### Rhabdomyosarcoma

### Chondrosarcoma (X + p)



#### Combination protons – Tomotherapy N. Fournier-Bidoz, C.Nauraye et al, PTCOG 2013



Fig.3: Dose distribution combining 55.8 GyE protons with 18 Gy tomotherapy (rectal wall in green, PTV\_55.8Gy in purple, PTV\_73.8Gy in dotted-red)



# Practical example (MGH)







Judy Adams et al, Skin sparing Lacrimal gland



### ROCOCO (Maastro & > 15 institutions involved)



Erik Roelofs et al, ROCOCO Trial, PTCOG 51, 2011



Conclusions (I) : see in the clinical presentations for each location that

- Planning with (passive) protons is "easy" as :
  - no dose behind the target
  - easy to conform lateraly (as photons)
  - no max dose at entrance
  - homogeneous dose to target
  - simple, not optimized but rather robust
- But be aware of the limitations and take care with:
  - Uncertainties in range
  - Deformation of shape if complex heterogeneities
  - High entrance dose mainly for superficial tumors
  - Care with small beams of complex shapes with small areas
  - Sensitivity to anatomical changes
  - Sensitivity to movements → for passive beams, and even more for dynamic beams (see later)



#### Conclusions (II)

- Importance of TPS validation, QA and users' experience for each plan, for the Treatment Planning System, for the full process
- Synergy & shared experience with photons, electrons, (IMXT, ...)
- Need to be able to provide safe treatments to a large population (social, ethics and business) : optimization of the throughput & combined treatments
- Comparative results in general are : Passive protons >> conventional photons Passive protons ~ > IMXT Intensity Mod PT > IMXT
- Need Gantries to plan all incidences as with photons
- Evolution to MonteCarlo, biological modelling ... and IMPT



## **Intensity Modulated IMPT-IMZT**



Trofimov, Kooy, Bortfeld, Lomax, ...



Next talk T. Lomax

1) TPS validation & QA : « Perturbations » by heterogeneities : Depth dose curves Water Level **Final Collimator** 200 MeV proton Beam 100 Inf%] ve Ionisatio 66 29 A.Mazal, Wanjie, China 50 150 100 Depth (mm)



1) TPS validation & QA :

Profiles in depth, modulated beam, low energy Measurements in Wanjie, China



#### 1) TPS validation & QA :



Ray tracing



Pencil beam

- antropomorphic phantom (skull + fat + air)
- shoot through beam
- Absolute comparison : isodoses in water fantom + TPS isodoses
- $\rightarrow$  gamma function (eg 2%, 2mm, or 3%, 3 mm...)



(R.Ferrand, L.DeMarzi et al)

2) Organ movementsLess sensitive with passive lines:

#### **Beam shaping laterally**

using scattering(or fast wobbling) :

#### Beam shaping in depth :

Spread out Bragg Peak Ridge filters or 1D scanning

Ex: 600 rpm 4 scans/rotation

= 40 scans/sec in depth (« fast repainting »)



## Towards dynamic delivery systems while being able to treat moving organs: « interplay » & « repainting » concepts











### Mitigation techniques :

- Breath holding
- Compression
- Beam Gating
- Beam Tracking
- Repainting

- ...

## **Intensity Modulated IMPT-IMZT**



Trofimov, Kooy, Bortfeld, Lomax, ...



Next talk T. Lomax